{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:03:11Z","timestamp":1777633391975,"version":"3.51.4"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Autoantibodies against metabolic regulators have been implicated in metabolic disorders; however, the clinical relevance of incretin-related autoantibodies in the development of hyperglycemia remains unclear. We investigated whether autoantibodies against glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are associated with future deterioration of glycemic status in a prospective cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed 218 participants who underwent health checkups and were followed for a mean of 8.1 years. Individuals with diabetes or baseline HbA1c \u2265 6.5% were excluded. Baseline serum anti-GIP and anti-GLP-1 antibody (Ab) levels were measured using AlphaLISA. Incident diabetes-range glycemia was defined as fasting plasma glucose \u2265 126 mg\/dL or HbA1c \u2265 6.5% without clinical confirmation, to avoid overestimation of incident diabetes in this cohort-based setting. Predictive performance was evaluated using receiver operating characteristic (ROC) analyses. To avoid overadjustment, HbA1c was excluded from the primary prediction models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>During follow-up, 21 participants developed diabetes-range glycemia. Baseline anti-GIP Ab levels were significantly higher in individuals who developed diabetes-range glycemia, whereas anti-GLP-1 Ab levels showed no association with risk. Anti-GIP Ab levels alone demonstrated modest but significant discriminative ability (AUC\u00a0=\u00a00.656). Although body mass index was a strong predictor (AUC\u00a0=\u00a00.799), adding anti-GIP Ab levels modestly improved model performance (AUC\u00a0=\u00a00.819).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Elevated baseline anti-GIP Ab levels were associated with the future development of diabetes-range glycemia and provided complementary predictive information beyond conventional metabolic risk factors. However, given the modest incremental improvement beyond BMI and the limited number of incident cases, the predictive contribution of anti-GIP antibody levels should be interpreted as exploratory and hypothesis-generating and requires validation in larger independent cohorts. These findings suggest that GIP-related immune responses may represent a distinct immunometabolic component involved in early glycemic deterioration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1811527","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T04:35:28Z","timestamp":1777437328000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Anti-GIP antibodies and future diabetes related risk: an eight-year prospective cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Takahide","family":"Hashimoto","sequence":"first","affiliation":[{"name":"Department of Diabetes, Metabolism and Endocrinology, School of Medicine, International University of Health and Welfare","place":["Narita, Chiba, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Ohtake","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Metabolism and Endocrinology, School of Medicine, International University of Health and Welfare","place":["Narita, Chiba, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tokiko","family":"Okamoto","sequence":"additional","affiliation":[{"name":"International University of Health and Welfare, Atami Hospital","place":["Atami, Shizuoka, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo-Shi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Graduate School of Medicine, Chiba University","place":["Chu-ku, Chiba, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoich","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Graduate School of Medicine, Chiba University","place":["Chu-ku, Chiba, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotaka","family":"Takizawa","sequence":"additional","affiliation":[{"name":"Port Square Kashiwado Clinic, Kashiwado Memorial Foundation","place":["Chuo-ku, Chiba, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Yamaga","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Metabolism and Endocrinology, School of Medicine, International University of Health and Welfare","place":["Narita, Chiba, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiko","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Metabolism and Endocrinology, School of Medicine, International University of Health and Welfare","place":["Narita, Chiba, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amika","family":"Kajiyama","sequence":"additional","affiliation":[{"name":"International University of Health and Welfare, Narita hospital","place":["Narita, Chiba, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Yagihashi","sequence":"additional","affiliation":[{"name":"International University of Health and Welfare, Narita hospital","place":["Narita, Chiba, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rikako","family":"Furukawa","sequence":"additional","affiliation":[{"name":"International University of Health and Welfare, Narita hospital","place":["Narita, Chiba, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaki","family":"Hiwasa","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Graduate School of Medicine, Chiba University","place":["Chu-ku, Chiba, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minoru","family":"Takemoto","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Metabolism and Endocrinology, School of Medicine, International University of Health and Welfare","place":["Narita, Chiba, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00730-2","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021","volume":"402","year":"2023","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1008862","article-title":"Diabetes mellitus, fasting glucose, and risk of cause-specific death","volume":"364","author":"Rao Kondapally Seshasai","year":"2011","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-023-05906-7","article-title":"The expanding incretin universe: from basic biology to clinical translation","volume":"66","author":"Drucker","year":"2023","journal-title":"Diabetologia"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-025-01183-8","article-title":"GLP-1-based therapies for diabetes, obesity and beyond","volume":"24","author":"Drucker","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2025.102118","article-title":"Glucose-dependent insulinotropic polypeptide (GIP)","volume":"95","author":"Muller","year":"2025","journal-title":"Mol Metab"},{"key":"B6","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12916-021-02001-9","article-title":"Serum anti-DIDO1, anti-CPSF2, and anti-FOXJ2 antibodies as predictive risk markers for acute ischemic stroke","volume":"19","author":"Hiwasa","year":"2021","journal-title":"BMC Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s12902-023-01491-3","article-title":"Serum anti-PCK1 antibody levels are a prognostic factor for patients with diabetes mellitus","volume":"23","author":"Namiki","year":"2023","journal-title":"BMC Endocr Disord"},{"key":"B8","doi-asserted-by":"publisher","first-page":"5391","DOI":"10.1038\/s41598-023-32644-y","article-title":"Association of high proprotein convertase subtilisin\/kexin type 9 antibody level with poor prognosis in patients with diabetes: a prospective study","volume":"13","author":"Yamagata","year":"2023","journal-title":"Sci Rep"},{"key":"B9","doi-asserted-by":"publisher","first-page":"38313","DOI":"10.1038\/s41598-025-22337-z","article-title":"Increased autoantibodies against incretin indicate poor prognosis in patients with diabetes","volume":"15","author":"Takemoto","year":"2025","journal-title":"Sci Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1042272","article-title":"Utility of atherosclerosis-associated serum antibodies against colony-stimulating factor 2 in predicting the onset of acute ischemic stroke and prognosis of colorectal cancer","volume":"10","author":"Li","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1089\/adt.2009.9996","article-title":"AlphaLISA immunoassay platform- the \"no-wash\" high-throughput alternative to ELISA","volume":"7","author":"Bielefeld-Sevigny","year":"2009","journal-title":"ASSAY Drug Dev Technol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25094935","article-title":"JMJD6 autoantibodies as a potential biomarker for inflammation-related diseases","volume":"25","author":"Zhang","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B13","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.2040-1124.2010.00022.x","article-title":"GIP and GLP-1, the two incretin hormones: similarities and differences","volume":"1","author":"Seino","year":"2010","journal-title":"J Diabetes Investig"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1431292","article-title":"Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists","volume":"15","author":"Liu","year":"2024","journal-title":"Front Endocrinol (Laus)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/dom.14496","article-title":"The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: a pathophysiological update","volume":"23","author":"Nauck","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1401149","article-title":"Long-acting glucose-dependent insulinotropic polypeptide ameliorates obesity-induced adipose tissue inflammation","volume":"193","author":"Varol","year":"2014","journal-title":"J Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvae151","article-title":"Hormonal regulation of human adipose tissue lipolysis: impact of adipose GIP system in overweight and obesity","volume":"192","author":"Brachs","year":"2025","journal-title":"Eur J Endocrinol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-23-0361","article-title":"The interplay of glucose-dependent insulinotropic polypeptide in adipose tissue","volume":"261","author":"Kagdi","year":"2024","journal-title":"J Endocrinol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410819","article-title":"Tirzepatide for obesity treatment and diabetes prevention","volume":"392","author":"Jastreboff","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1811527\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T04:35:35Z","timestamp":1777437335000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1811527\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":19,"alternative-id":["10.3389\/fendo.2026.1811527"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1811527","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"article-number":"1811527"}}